HIM
NPCE icon

Hillsdale Investment Management’s Neuropace NPCE Stock Holding History

Hillsdale Investment Management’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,750
Closed -$155K – 662
2024
Q1 		$155K Buy
+11,750
New +$168K 0.01% 399

Other funds holding NPCE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
KLC
Kent Lake Capital Reno, Nevada $222M AUM 18.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hillsdale Investment Management's NPCE Position: Q2 2024 in Review

Hillsdale Investment Management sold out of Neuropace (NPCE) in Q2 2024, closing a stake of 11,750 shares — an estimated $155K sold.

Hillsdale Investment Management first reported a position in NPCE in Q1 2024 and held it in 1 quarter. The position peaked at $155K in Q1 2024. 51 funds tracked by Wall St. Rank hold NPCE as of Q2 2024.

  • Hillsdale Investment Management reported no remaining Neuropace position as of Q2 2024 after selling out during the quarter.
  • Hillsdale Investment Management sold 11,750 Neuropace shares in Q2 2024, an estimated $155K.
  • Hillsdale Investment Management first reported a position in Neuropace in Q1 2024 and held it in 1 quarter.
  • Hillsdale Investment Management's Neuropace position peaked at $155K in Q1 2024.
  • 51 funds tracked by Wall St. Rank held Neuropace as of Q2 2024.

Based on Hillsdale Investment Management's 13F filing for Q2 2024, filed 13 Aug 2024.